Home › Compare › TRVN vs RYLD

TRVN vs RYLD: Dividend Comparison 2026

TRVN yields 18018.02% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRVN wins by $18633001307266260992.00M in total portfolio value
10 years
TRVN
TRVN
● Live price
18018.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18633001307266260992.00M
Annual income
$18,431,768,966,926,280,000,000,000.00
Full TRVN calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — TRVN vs RYLD

📍 TRVN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRVNRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRVN + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRVN pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRVN
Annual income on $10K today (after 15% tax)
$1,531,531.53/yr
After 10yr DRIP, annual income (after tax)
$15,667,003,621,887,337,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, TRVN beats the other by $15,667,003,621,887,337,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRVN + RYLD for your $10,000?

TRVN: 50%RYLD: 50%
100% RYLD50/50100% TRVN
Portfolio after 10yr
$9316500653633130496.00M
Annual income
$9,215,884,483,463,140,000,000,000.00/yr
Blended yield
98.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TRVN right now

TRVN
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
Altman Z
-48.2
Piotroski
3/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRVN buys
0
RYLD buys
0
No recent congressional trades found for TRVN or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRVNRYLD
Forward yield18018.02% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$18633001307266260992.00M ✓$44.5K
Annual income after 10y$18,431,768,966,926,280,000,000,000.00 ✓$2,587.35
Total dividends collected$18619711198521020416.00M ✓$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: TRVN vs RYLD ($10,000, DRIP)

YearTRVN PortfolioTRVN Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$1,812,502$1,801,801.80$11,914$1,213.65+$1.80M → TRVN
2$307,151,434$305,212,057.22$14,099$1,351.30+$307.14M → TRVN
3$48,667,022,851$48,338,370,816.14$16,580$1,494.55+$48667.01M → TRVN
4$7,210,053,431,136$7,157,979,716,686.14$19,384$1,642.61+$7210053.41M → TRVN
5$998,798,584,418,300$991,083,827,246,983.60$22,535$1,794.70+$998798584.40M → TRVN
6$129,380,351,742,642,780$128,311,637,257,315,230.00$26,063$1,950.00+$129380351742.62M → TRVN
7$15,672,057,030,122,314,000$15,533,620,053,757,686,000.00$29,995$2,107.69+$15672057030122.28M → TRVN
8$1,775,286,122,699,574,700,000$1,758,517,021,677,343,500,000.00$34,361$2,266.99+$1775286122699574.75M → TRVN
9$188,067,607,794,372,840,000,000$186,168,051,643,084,300,000,000.00$39,194$2,427.12+$188067607794372832.00M → TRVN
10$18,633,001,307,266,260,000,000,000$18,431,768,966,926,280,000,000,000.00$44,525$2,587.35+$18633001307266260992.00M → TRVN

TRVN vs RYLD: Complete Analysis 2026

TRVN — Stock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Full TRVN Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this TRVN vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRVN vs SCHDTRVN vs JEPITRVN vs OTRVN vs KOTRVN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.